Tocilizumab Treatment in COVID-19 Patients: Comparing Cutaneous Disease and Adverse Drug Effects

Angela Rosenberg; Jacquelyn D. Waller; Mindy D. Szeto; Kayd J. Pulsipher; Cheryl A. Bloomfield; Colby L. Presley; Robert P. Dellavalle

doi:10.36849/JDD.6532e

Tocilizumab Treatment in COVID-19 Patients: Comparing Cutaneous Disease and Adverse Drug Effects

Angela Rosenberg, Jacquelyn D. Waller, Mindy D. Szeto, Kayd J. Pulsipher, Cheryl A. Bloomfield, Colby L. Presley, Robert P. Dellavalle

Research output: Contribution to journal › Letter › peer-review

Abstract

Actemra (tocilizumab) received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19) in June 2021. Literature has linked numerous cutaneous adverse effects to tocilizumab. In this current survey, investigators reviewed and compared these adverse effects to the common cutaneous manifestations of COVID-19. While similarities in patient presentation exist, important distinctions are made to aid dermatologists in their clinical diagnosis.

Original language	English (US)
Pages (from-to)	E42-E43
Journal	Journal of Drugs in Dermatology
Volume	22
Issue number	12
DOIs	https://doi.org/10.36849/JDD.6532e
State	Published - Dec 2023
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2023 Novel Carbon Resource Sciences. All rights reserved.

PubMed: MeSH publication types

Editorial

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.36849/JDD.6532e

Find It

Find It at U of M Libraries

Cite this

@article{b802016d03d4421f8cf5f2f47bf69354,

title = "Tocilizumab Treatment in COVID-19 Patients: Comparing Cutaneous Disease and Adverse Drug Effects",

abstract = "Actemra (tocilizumab) received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19) in June 2021. Literature has linked numerous cutaneous adverse effects to tocilizumab. In this current survey, investigators reviewed and compared these adverse effects to the common cutaneous manifestations of COVID-19. While similarities in patient presentation exist, important distinctions are made to aid dermatologists in their clinical diagnosis.",

author = "Angela Rosenberg and Waller, {Jacquelyn D.} and Szeto, {Mindy D.} and Pulsipher, {Kayd J.} and Bloomfield, {Cheryl A.} and Presley, {Colby L.} and Dellavalle, {Robert P.}",

year = "2023",

month = dec,

doi = "10.36849/JDD.6532e",

language = "English (US)",

volume = "22",

pages = "E42--E43",

journal = "Journal of Drugs in Dermatology",

issn = "1545-9616",

publisher = "Journal of Drugs in Dermatology",

number = "12",

}

TY - JOUR

T1 - Tocilizumab Treatment in COVID-19 Patients

T2 - Comparing Cutaneous Disease and Adverse Drug Effects

AU - Rosenberg, Angela

AU - Waller, Jacquelyn D.

AU - Szeto, Mindy D.

AU - Pulsipher, Kayd J.

AU - Bloomfield, Cheryl A.

AU - Presley, Colby L.

AU - Dellavalle, Robert P.

PY - 2023/12

Y1 - 2023/12

N2 - Actemra (tocilizumab) received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19) in June 2021. Literature has linked numerous cutaneous adverse effects to tocilizumab. In this current survey, investigators reviewed and compared these adverse effects to the common cutaneous manifestations of COVID-19. While similarities in patient presentation exist, important distinctions are made to aid dermatologists in their clinical diagnosis.

AB - Actemra (tocilizumab) received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19) in June 2021. Literature has linked numerous cutaneous adverse effects to tocilizumab. In this current survey, investigators reviewed and compared these adverse effects to the common cutaneous manifestations of COVID-19. While similarities in patient presentation exist, important distinctions are made to aid dermatologists in their clinical diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=85178850439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85178850439&partnerID=8YFLogxK

U2 - 10.36849/JDD.6532e

DO - 10.36849/JDD.6532e

M3 - Letter

C2 - 38051828

AN - SCOPUS:85178850439

SN - 1545-9616

VL - 22

SP - E42-E43

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

IS - 12

ER -

Tocilizumab Treatment in COVID-19 Patients: Comparing Cutaneous Disease and Adverse Drug Effects

Abstract

Bibliographical note

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this